Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: A high intensity discharge lamp includes an arc tube with a chemical fill, capillaries extended from the arc tube, electrodes fed through the capillaries into the arc tube, and a frit seal that seals the capillaries, where the frit seal includes silica (SiO2) in a range of more than 0 wt % to less than 5 wt %, alumina (Al2O3), and one of dysprosia (Dy2O3) and yttrium oxide (Y2O3). This frit seal material can withstand a higher operating temperature so that the length of the capillaries can be reduced compared to those sealed with conventional frit seal material.

Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

Abstract: A high intensity discharge lamp includes an arc tube with a chemical fill, capillaries extended from the arc tube, electrodes fed through the capillaries into the arc tube, and a frit seal that seals the capillaries, where the frit seal includes silica (SiO2) in a range of more than 0 wt % to less than 5 wt %, alumina (Al2O3), and one of dysprosia (Dy2O3) and yttrium oxide (Y2O3). This frit seal material can withstand a higher operating temperature so that the length of the capillaries can be reduced compared to those sealed with conventional frit seal material.

Abstract: The present invention relates to naphthalene derivatives of formula (I) that are modulators of the glucocorticoid receptor, and to processes for the preparation and use of the same.

Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

Abstract: A ceramic arc tube having an integral susceptor for RF inductive sealing is described. The integral susceptor in the form of an electrically conductive coating is applied directly to the surface of the arc tube in the seal region. This enables RF heating which is sufficient to melt a frit material and hermetically seal the arc tube. The integral susceptor further provides for a more controlled placement of the seal.

Abstract: A method of bonding two ceramic parts to each other includes the steps of preparing a water-based slurry from Al2O3 powder and Y(NO3)3 solution in amounts that yield a eutectic compound of Al2O3 and Y2O3 when heated, placing the slurry in liquid, solid or gaseous form in direct contact with two ceramic parts that are to be bonded to each other, and heating the slurry to a temperature that bonds the two ceramic parts to each other. The method is particularly useful to join two ceramic parts where one is comprised of polycrystalline alumina and the other is comprised of one of single crystal alumina and polycrystalline alumina, such as an arc discharge vessel for a high intensity discharge lamp.

Abstract: An arc discharge vehicle lamp (10) for nebulous weather comprising a body (12) defining a chamber (14) having a volume of between 0.025 to 0.035 cc and including spaced apart electrodes (16, 18) having an arc gap (20) of between 2 and 6 mm; and an arc generating and sustaining medium (21) in the chamber for developing light having a color temperature between 1800K to 2800K during operation of the lamp. A preferred arc gap is 4.2 mm. The electrodes (16 and 18) are preferably fashioned with three parts; a niobium sealing region, an intermediate region of molybdenum and a tungsten region, which protrudes into the discharge chamber.

Abstract: A ceramic arc tube having an integral susceptor for RF inductive sealing is described. The integral susceptor in the form of an electrically conductive coating is applied directly to the surface of the arc tube in the seal region. This enables RF heating which is sufficient to melt a frit material and hermetically seal the arc tube. The integral susceptor further provides for a more controlled placement of the seal.